ICON PLC ICLR
- Market cap
- $13.4B
- P/E
- 257×
Follow ICLR
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.31 | 74.30 | 101.22 | 118.10 | 104.28 | 168.76 | 171.43 | 181.92 | 183.38 | 125.10 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 85.74 | 124.48 | 155.33 | 172.45 | 215.29 | 313.00 | 312.28 | 288.50 | 347.72 | 228.29 |
High Price
|
|||
| 12,500 | 13,250 | 13,670 | 14,650 | 15,730 | 38,330 | 41,100 | 41,100 | 41,900 | 40,100 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 1,666 | 1,758 | 2,596 | 2,806 | 2,797 | 5,481 | 7,741 | 8,120 | 8,189 | 8,251 |
Revenue
|
|||
| 42.31% | 41.58% | 29.95% | 29.64% | 29.22% | 27.52% | 28.60% | 29.56% | 28.95% | 26.37% |
Gross Margin
|
|||
| 300 | 328 | 365 | 427 | 381 | 197 | 568 | 624 | 804 | 252 |
EBT
|
|||
| 18.01% | 18.66% | 14.05% | 15.22% | 13.63% | 3.59% | 7.34% | 7.69% | 9.82% | 3.06% |
EBT Margin
|
|||
| 262 | 281 | 323 | 376 | 333 | 153 | 505 | 612 | 739 | 229 |
Net Income
|
|||
| 60 | 61 | 66 | 92 | 66 | 315 | 570 | 586 | 489 | 383 |
Depreciation
|
|||
| 30.16 | 32.49 | 47.96 | 52.10 | 52.92 | 81.67 | 94.95 | 98.90 | 99.28 | 105.21 |
Revenue/Sh
|
|||
| 4.87 | 5.20 | 6.17 | 6.85 | 6.20 | 2.28 | 6.20 | 7.46 | 9.60 | 2.92 |
Earnings/Sh
|
|||
| 4.69 | 7.08 | 4.96 | 7.66 | 10.75 | 12.36 | 6.91 | 14.14 | 15.60 | 13.21 |
Cash Flow/Sh
|
|||
| (0.77) | (0.83) | (0.89) | (0.94) | (0.77) | (1.40) | (1.74) | (1.71) | (2.04) | (2.22) |
Capex/Sh
|
|||
| 3.92 | 6.25 | 4.07 | 6.72 | 9.97 | 10.96 | 5.17 | 12.43 | 13.56 | 10.99 |
Free CF/Sh
|
|||
| 17.11 | 22.00 | 25.02 | 30.78 | 35.00 | 120.20 | 104.23 | 112.55 | 114.46 | 117.23 |
Book Value/Sh
|
|||
| 55 | 54 | 54 | 54 | 53 | 67 | 82 | 82 | 82 | 78 |
Shares
|
|||
| 15.53 | 22.06 | 21.68 | 25.14 | 31.45 | 102.89 | 31.27 | 37.64 | 23.39 | 70.64 |
PE Ratio
|
|||
| 2.48 | 3.52 | 2.69 | 3.31 | 3.68 | 3.79 | 2.04 | 2.84 | 2.11 | 1.73 |
PS Ratio
|
|||
| 4.37 | 5.20 | 5.16 | 5.60 | 5.57 | 2.58 | 1.86 | 2.49 | 1.83 | 1.55 |
PB Ratio
|
|||
| 2.74 | 3.72 | 2.79 | 3.26 | 3.52 | 4.65 | 2.60 | 3.26 | 2.46 | 2.07 |
EV/Sales
|
|||
| 21.08 | 19.31 | 32.86 | 25.24 | 18.66 | 34.63 | 47.84 | 25.92 | 18.04 | 19.77 |
EV/FCF
|
|||
| 259 | 383 | 269 | 413 | 568 | 829 | 563 | 1,161 | 1,287 | 1,036 |
Op' Cash Flow
|
|||
| (43) | (45) | (48) | (51) | (41) | (94) | (142) | (141) | (168) | (174) |
Capex
|
|||
| 217 | 338 | 220 | 362 | 527 | 735 | 421 | 1,020 | 1,119 | 862 |
FCF
|
|||
| 464 | 535 | 720 | 494 | 979 | 462 | 538 | 586 | 640 | 306 |
Working Cap'
|
|||
| 349 | 349 | 349 | 427 | 372 | 5,436 | 4,654 | 3,776 | 3,426 | 3,402 |
Total Debt
|
|||
| 88 | (12) | (106) | (143) | (470) | 4,682 | 4,364 | 3,396 | 2,887 | 2,755 |
Net Debt
|
|||
| 945 | 1,191 | 1,354 | 1,658 | 1,850 | 8,067 | 8,498 | 9,241 | 9,441 | 9,193 |
Sh' Equity
|
|||
| 14.80% | 14.17% | 14.34% | 14.22% | 10.48% | 1.47% | 2.92% | 3.58% | 4.40% | 1.39% |
ROA
|
|||
| 18.86% | 17.93% | 18.70% | 17.89% | 17.72% | 1.86% | 3.86% | 4.73% | 5.23% | 2.32% |
ROIC
|
|||
| 30.70% | 26.35% | 25.35% | 24.83% | 18.95% | 3.09% | 6.10% | 6.90% | 7.91% | 2.46% |
ROE
|
|||
ICON PLC peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CRL Charles River Laboratories International, Inc. | $14.1B | 0.0× | Compare |
| TWST Twist Bioscience Corporation | $12.4B | 0.0× | Compare |
| RVTY Revvity Inc. | $16.8B | 72.0× | Compare |
| MEDP Medpace Holdings, Inc. | $17.3B | 35.6× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QGEN QIAGEN N.V. | $9.3B | 22.6× | Compare |
| LH Labcorp Holdings Inc. | $21.9B | 25.4× | Compare |
| GH Guardant Health, Inc. | $23.9B | 0.0× | Compare |
| DGX Quest Diagnostics Incorporated | $26.2B | 24.8× | Compare |
ICON PLC (ICLR) key facts
- ICON PLC (ICLR) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- As of September 25, 2026, ICLR traded at $172.33, a market capitalization of $13.4 billion.
- Return on equity was 2.46% and debt-to-equity 0.36.
ICON PLC (ICLR) Latest News
22 Sep
Marram Investment Management’s Q2 2026 letter shows a +2.7% Q2 portfolio return (net) and +3.2% year-to-date, with ICON Public Limited Company (ICLR) among the holdings. Marram exited ICON at breakeven after research showed its moat deteriorating faster than expected amid unhealthy industry competition and reduced pricing power, a trend likely worsened by AI-enabled cost efficiencies driving price cuts. ICON traded around $169.55 on Sept. 21, 2026, with a 52-week range of $66.57–$203.91 and a market cap near $13.1B. Hedge-fund data show 39 portfolios owned ICON at Q2 end, down from 49, reflecting cautious sentiment. The letter contrasts ICON with higher-upside AI names, suggesting downside risk for ICON’s positioning. Negative reassessment of ICON's moat and pricing power signals potential downside for margins and competitive position.
6 Aug
ICON PLC valuation improves but earnings risks persist, raising questions on buy status. Valuation gains offset by earnings risks point to moderate influence on ICON PLC trajectory.
ICON PLC prices USD 2.15 billion notes. Large note issuance affects ICON PLC capital structure and funding for operations.
5 Aug
ICON PLC partners with Anthropic to integrate AI into clinical trials. AI collaboration targets core trial operations and competitive positioning for ICON.
ICON PLC (ICLR) shares rise 33.2% over three months amid strengthening recovery expectations. Strengthening recovery expectations support moderately positive effects on near-term market sentiment and performance.
4 Aug
ICON plc (ICLR) stock surged 57% in Q2 after accounting clarity. Accounting clarity resolved uncertainties and drove major stock gains that can shift investor sentiment and company trajectory.
30 Jul
ICON PLC (ICLR) presented Q2 earnings call highlights covering financial results and operational updates. Q2 earnings highlights deliver performance metrics and guidance that can materially shift investor views on ICON PLC.
ICON PLC reported a surge in bookings for Q2 2026 amid ongoing margin pressures during its earnings call. Strong bookings signal potential revenue growth but persistent margin pressures limit overall trajectory shifts.
29 Jul
ICON PLC (ICLR) stock surges on strength in net book-to-bill ratio reflecting solid new contract momentum. Robust net book-to-bill directly signals higher future revenue backlog and improved growth trajectory for ICON.
ICON PLC reported its second quarter 2026 financial results. Quarterly results disclosures typically drive noticeable but limited shifts in valuation and sentiment.
28 Jul
ICON PLC announces multi-year collaboration with Anthropic to integrate AI across clinical trials. Multi-year AI partnership targets core clinical trial operations and could materially improve efficiency plus competitive positioning.
ICON PLC announces multi-year collaboration with Anthropic to integrate frontier AI into clinical trials. Multi-year AI partnership targets core clinical trial operations with potential to materially enhance efficiency and competitive positioning.
22 Jul
ICON Plc (ICLR) demonstrates recovery and strengthening after encountering challenges. Recovery signals in ICON Plc may moderately influence its market performance and investor sentiment.
15 Jul
ICON PLC (ICLR) Q2 earnings are expected to decline. Expected earnings decline may pressure stock performance and investor sentiment.
8 Jul
ICON PLC stock is positioned for its next growth phase amid evolving CRO industry trends that could shape operational and market dynamics. CRO trends may moderately influence ICON PLC financial performance and competitive positioning without fundamentally altering its trajectory.
25 Jun
RBC Capital Markets states ICON PLC has reestablished a credible path to growth in 2027. Analyst note on restored growth path may lift investor sentiment and share price modestly.
24 Jun
ICON PLC reported strong bookings and strategic expansions in its Q1 2026 earnings call. Strong bookings signal improved revenue visibility and growth for ICON PLC.
ICON PLC stock surged sharply on Wednesday amid positive developments driving investor gains. Stock surge reflects short-term positive momentum without evidence of fundamental long-term shifts.
ICON Public Limited Company conducted its Q1 2026 earnings call, covering financial results and operational updates. Quarterly earnings calls provide financial metrics and guidance that moderately influence near-term stock sentiment and valuation.
23 Jun
ICON PLC reported its first quarter 2026 financial results. Quarterly results release supplies updated financial metrics that can move investor views and near-term trading.
22 Jun
ICON PLC selects Microsoft as preferred technology partner to power AI-enabled clinical development. AI partnership targets core clinical operations and can materially improve efficiency and competitive positioning.
3 Jun
ICON (ICLR) shares surge 20.8% on 2026 outlook release, share buyback plan and governance overhaul. Buyback and governance changes represent major strategic moves that can significantly shift company trajectory and sentiment.
29 May
ICON PLC reported Q4 2025 results and outlook during its earnings call, covering revenue, margins, contract wins, and 2026 guidance. Quarterly earnings updates supply performance data and guidance that can shift near-term sentiment and valuation multiples.
28 May
ICON PLC reported strong bookings in Q4 2025 earnings call despite ongoing revenue challenges. Mixed Q4 earnings signals from bookings strength versus revenue weakness point to moderate effects on ICON PLC performance outlook.
ICON PLC reported Q4 earnings during its call, covering financial results, operational metrics and forward guidance for the clinical research services business. Quarterly earnings and guidance directly inform near-term revenue expectations and valuation multiples for the company.
27 May
ICON PLC reported fourth quarter and full year 2025 results and disclosed the outcome of its Audit Committee investigation. Quarterly results offer routine updates while audit findings may affect short-term investor views on controls without altering core operations.
18 May
ICON PLC stands to gain from heightened clinical trial activity and established ties to major pharmaceutical companies, according to RBC. RBC's positive assessment of rising trial volumes and pharma relationships can lift near-term sentiment and share price for ICON.
13 May
ICON PLC expands its US early phase research capabilities by opening a new clinic and outpatient centers. New US clinic and outpatient centers represent a major strategic expansion enhancing ICON's early phase research capacity and competitive positioning.
5 May
HealthVerity to acquire Symphony Health, uniting clinical data and commercial analytics to accelerate breakthroughs across the healthcare ecosystem. HealthVerity's acquisition of Symphony Health, as ICON's recent subsidiary, significantly enhances ICON's real-world data and analytics capabilities for clinical research.
29 Apr
ICON PLC updates on ongoing Audit Committee investigation into certain matters and delays release of Q4 and full-year 2025 financial results, now expected in late March 2025, amid review of accounting practices. Audit investigation and earnings delay signal potential accounting issues that could lead to restatements, eroding investor trust and pressuring stock price.